KLK3 and prostate carcinoma: Evidence for the stimulation of Vγ2Vδ 2-bearing T cells by N-BPs has also been observed in MM patients treated with palmidronic acid (4) (Kunzmann et al., 1999) and prostate cancer patients treated with zoledronic acid (1a) (Naoe et al., 2010); in the latter case, the observed T cell effects coincided with reduction in serum prostate-specific antigen (PSA), providing further evidence of an antitumor immune response in vivo (Naoe et al., 2010).